Pfizer Inc. $PFE Shares Purchased by Saudi Central Bank

Posted by George Bondi on Sep 6th, 2026

Saudi Central Bank raised its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 23.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 976,902 shares of the biopharmaceutical company’s stock after purchasing an additional 188,320 shares during the quarter. Saudi Central Bank’s holdings in Pfizer were worth $24,085,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Evolution Wealth Management Inc. lifted its holdings in shares of Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 566 shares during the period. Godfrey Financial Associates Inc. acquired a new position in Pfizer during the fourth quarter worth $26,000. Keb Asset Management LLC purchased a new position in Pfizer in the second quarter worth $26,000. HFM Investment Advisors LLC raised its position in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares in the last quarter. Finally, Field & Main Bank acquired a new stake in Pfizer in the second quarter valued at $27,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer received FDA approval for the 2026–2027 COMIRNATY XFG COVID-19 vaccine formulation for high-risk age groups. The approval supports continued vaccine revenue and adds to the company’s recent positive news flow. Pfizer After FDA Vaccine Approval Faces A Fair Value Reality Check
Positive Sentiment: Pfizer launched the VESPER-JM Phase 3 study of berobenatide in Japan, strengthening its effort to compete in the obesity-drug market. Successful development could provide a meaningful long-term growth opportunity beginning later this decade. Pfizer Steps Up in Obesity Race With New Phase 3 Berobenatide Trial in Japan
Positive Sentiment: Pfizer’s broader pipeline remains focused on obesity and oncology, with berobenatide and next-generation cancer treatments viewed as potential growth drivers from 2028 onward. Pfizer’s Pipeline Strategy Centers on Obesity and Oncology
Positive Sentiment: Pfizer licensed its early-stage CD228V antibody-drug conjugate to Medicus Pharma in a deal valued at up to $1 billion plus royalties. The agreement could generate milestone and royalty income while sharing development responsibilities. Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
Neutral Sentiment: Pfizer completed a Phase 1 migraine-tablet study and is conducting a Phase 3 trial of tilrekimig for eczema. These updates demonstrate pipeline activity, but they do not yet provide confirmed commercial revenue. Pfizer’s Tilrekimig Eczema Trial
Negative Sentiment: After gaining roughly 25% over the past year and trading near recent highs, valuation-based upside appears more limited. Investors are also weighing Pfizer’s elevated dividend yield and management’s commitment to maintaining the payout against ongoing post-pandemic earnings pressure.

Pfizer Stock Performance

Pfizer stock opened at $28.42 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $29.21. The company has a market cap of $161.98 billion, a price-to-earnings ratio of 37.40, a price-to-earnings-growth ratio of 1.91 and a beta of 0.34. The stock’s 50-day moving average is $25.98 and its 200-day moving average is $26.34.

Pfizer (NYSE:PFE – Get Free Report) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 1st. Investors of record on Friday, July 24th were issued a dividend of $0.43 per share. The ex-dividend date was Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.1%. Pfizer’s payout ratio is presently 226.32%.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent analyst reports. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research note on Monday, July 6th. JPMorgan Chase & Co. dropped their target price on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Wolfe Research restated an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. Finally, Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a research note on Tuesday, June 9th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $28.28.

Check Out Our Latest Analysis on PFE

Pfizer Company Profile

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.